Lably
Skip to content

Benralizumab

Monoclonal antibody

  • 1 min read
  • 1 chapter

Explore on Lably

ToursExplore Lably’s 3D tours

Two phase III clinical trials of benralizumab reported meeting their primary endpoints in 2016. It was approved by the US Food and Drug Administration in November 2017 for the treatment of severe eosinophilic asthma. It was granted designation as an orphan drug by the Food and Drug Administration for treatment of eosinophilic oesophagitis in August 2019.

Common adverse effects include injection site reactions, which were reported in 2.2% of patients (vs. 1.9% for placebo) in clinical trials.

Clinical trials

In November 2024, the ABRA study found that a single dose of benralizumab could be more effective when injected at the point of exacerbation compared to currently used steroid tablets in patients at high risk of an asthma or chronic obstructive pulmonary disease (COPD).

More in Health

Food and Drug AdministrationFederal agency of the United States Department of Health and Human ServicesCenters for Disease Control and PreventionUnited States government public health agencyNauseaMedical symptom or conditionSeizurePeriod of symptoms due to excessive or synchronous neuronal brain activityVomitingExpulsion of stomach contents via the mouth or noseIntravenous therapyMedication administered into a vein